Treatment
Anumonye reported treatment success with lorazepam; others found benefit with antidepressants and relaxation exercises. Epidemiology
BFS has been reported in other African cultures, and also in Brazil, Argentina, and Ethiopian Jews. Historic higher reported prevalence among males may be due to more males being present in higher education in African countries. Studies since the 1990s have not verified gender differences. Other studies found a possible association with low socioeconomic status, an association with average or higher intelligence, and a high association with neuroticism. Individuals with BFS have been found to have problems with isolation, poor study habits, and the use of psychostimulants as well as physical changes including in muscle tension and heart rate. History
The condition was first described by R. H. Prince who named the condition based on the term brain fag used by students who believed their symptoms were attributed to "brain fatigue". However, this term was used in the United States and Europe dating back to 1839. Furthermore, in a detailed historical account, Ayonrinde (2020) illustrates that contrary to widely held and published belief in diagnostic manuals, psychiatric, social science and educational text, the term "Brain Fag" and associated syndromes of anxiety, affective and somatoform symptoms in student and "brain worker" populations were first described in nineteenth century Britain (Tunstall, 1850) with dissemination across the British Empire. Ayonrinde concludes that, the time has come for the decolonization of brain fag and its African syndromization in the true spirit of ethical scientific rigor in the twenty-first century. See also
Burnout
Exhaustion


== References ==
The decision, which has been claimed by Novartis to be based on a recommendation by unnamed bioethicists, was received with much criticism by the European Commission, some European healthcare regulators and patient groups who see it as emotionally burdening, suboptimal, and ethically questionable. Novartis did not consult with families or doctors before announcing the scheme. Names
Onasemnogene abeparvovec is the international nonproprietary name (INN) and the United States Adopted Name (USAN). References
External links
"Onasemnogene abeparvovec". Drug Information Portal. U.S. National Library of Medicine.